Ann: Immutep Corporate Presentation, page-84

not sure if this helps with your question...
TACTI-002 is expected to complete in May 2022. (expected dates on available on company's website)
AIPAC (in mBC) - the most advanced trial is targeted to complete in March this year. If it goes to plan, it will line up nicely with ASCO timing in June. If the completion is delayed, it's not a bad thing as patients are surviving longer than expected.
For other fellow shareholders, thanks for your ongoing discussions. I always learn stuff from your posts. I'm not against the broker reports, they summarise data systematically and apply probability of trial success. I did get a copy of the Bell Porter report without being a client of them. You need to ring up bell porter and ask for it nicely...they don't allow forwarding the report though.